AbbVie
AbbVie is a global, research-based biopharmaceutical company focused on developing and marketing advanced therapies for complex and serious diseases. The company maintains leadership positions in several high-growth therapeutic areas including immunology, oncology, neuroscience, and aesthetics. Its value proposition is centered on clinical innovation and a diversified portfolio of proprietary medicines that address significant unmet medical needs.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Biopharmaceutical Products
primaryA single global business segment focused on the research, development, manufacturing, and commercialization of innovative medicines across multiple therapeutic areas.
Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Elahere, Epkinly, Vraylar, Botox Therapeutic, Ubrelvy, Qulipta, Vyalev, Duodopa, Ozurdex, Lumigan, Alphagan, Mavyret, Creon, Linzess
Wholesale distributors, Specialty pharmacies, Government agencies, Health care facilities, Retailers
Aesthetics
majorA specialized portfolio of facial injectables, body contouring, and skincare products marketed globally to healthcare providers and consumers.
Botox Cosmetic, Juvederm Collection, CoolSculpting, SkinMedica, Natrelle, Alloderm, Latisse, DiamondGlow
Physicians, Licensed healthcare providers, Medical spas, Direct-to-consumer
Segment Financials
International — Collaboration revenues
View metricBusiness Overview
Competitive Position
A global leader in immunology and aesthetics with a dominant market share in biologic therapies, currently managing the transition of its legacy blockbuster portfolio toward newer growth assets.
Geographies
North America, European Union, Japan, China, Global
Customer Segments
Hospitals, Physicians, Managed Care Providers, Government Agencies, Pharmacy Benefit Managers
Upstream Dependencies
Raw material suppliers, Specialized chemical manufacturers, Clinical research organizations, Biologics infrastructure providers
Downstream Customers
Wholesale pharmaceutical distributors, Retail pharmacies, Hospitals and health systems, Government health programs (Medicaid, VA), Specialty clinics
Competitors & Partners
Competitors
Johnson & Johnson
JNJ
Competitor in immunology and oncology
Amgen
AMGN
Competitor in immunology and biosimilars
Pfizer
PFE
Competitor in immunology and oncology
Eli Lilly
LLY
Competitor in immunology and neuroscience
McKesson
MCK
Major wholesale distributor (customer/partner context)
Cencora
COR
Major wholesale distributor (customer/partner context)
Cardinal Health
CAH
Major wholesale distributor (customer/partner context)
Vertex Pharmaceuticals
VRTX
Competitor in cystic fibrosis research and general specialty medicine
Partners
Subsidiaries
Allergan
Acquired aesthetics and neuroscience business unit
ImmunoGen
Acquired oncology-focused subsidiary (developer of Elahere)
AbbVie FAQ
Common questions about AbbVie
AbbVie is a global, research-based biopharmaceutical company focused on developing and marketing advanced therapies for complex and serious diseases. The company maintains leadership positions in several high-growth therapeutic areas including immunology, oncology, neuroscience, and aesthetics. Its value proposition is centered on clinical innovation and a diversified portfolio of proprietary medicines that address significant unmet medical needs.
AbbVie (ABBV) has a market capitalization of $378.98B and trades on NYSE.
AbbVie generated $62.8B in trailing twelve-month revenue with net income of $3.6B, representing a net margin of 5.8%. Gross margin stands at 70.7%, with free cash flow of $20.0B. These figures are based on the Q1 2026 filing.
AbbVie's key competitors include Johnson & Johnson, Amgen, Pfizer, and others. These companies compete in similar markets and product categories.
AbbVie has approximately 50,000 employees.